OncoMyx: creating a systemic, multi-warhead, non-human oncolytic virus

Nearly 50 companies are developing oncolytic viruses, but only OncoMyx is developing a non-human pathogenic myxoma virus capable of carrying multiple warheads and amenable to systemic administration. 

That mix of properties was characterized by Grant McFadden’s lab at Arizona State University, which OncoMyx Therapeutics Inc. spun out of in 2018. Co-founder and CEO Steven Potts, who was VP of global medical and diagnostic affairs at Ignyta Inc. from 2015 to 2018, told BioCentury he was looking to develop a cancer treatment with broader impact than Ignyta’s Rozlytrek entrectinib, a tissue-agnostic oncology drug indicated for NTRK fusion-positive solid tumors, which comprise fewer than 1% of cancers. ...